ArticleBMC cancer2025
Elevated miR-221-3p inhibits epithelial-mesenchymal transition and biochemical recurrence of prostate cancer via targeting KPNA2: an evidence-based and knowledge-guided strategy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating miRNA profiling and machine learning for improved prostate cancer diagnosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is commonly occurred among males worldwide and its prognosis could be influenced by biochemical recurrence (BCR). MicroRNAs (miRNAs) are functional regulators in carcinogenesis, and miR-221-3p was reported as one of the significant candidates deregulated in PCa. However, its regulatory pattern in PCa BCR across literature reports was not consistent, and the targets and mechanisms in PCa malignant transition and BCR are less explored.
methodsIn this study, an evidence-based and knowledge-guided approach was proposed to decipher the role and mechanism of miR-221-3p in PCa development. First, the literature-reported inconsistency between miR-221-3p and PCa BCR was quantitatively measured by meta-analysis. Then a knowledge-guided network strategy was applied to prioritize key targets of miR-221-3p in PCa progression based both on topological and functional characterization of genes in multi-omics miRNA-mRNA and protein-protein interaction networks. Finally, a key gene was computationally identified and experimentally validated using cell line and clinical samples through EdU assay, scratch assay, transwell assay, dual-luciferase reporter assay and the epithelial-to-mesenchymal transition (EMT)-related analysis.
resultsDown-regulation of miR-221-3p was correlated with a lower biochemical recurrence-free survival (BRFS) in PCa (HR: 0.72, 95%, CI: 0.64-0.81, P < 0.00001). A significant down-regulation of miR-221-3p was observed in most of the PCa cells compared with the normal control. KPNA2 was identified as a key target of miR-221-3p and it was over-expressed in all the PCa cells and human PCa tissues. Moreover, elevated miR-221-3p inhibited the proliferation, migration, invasion, and EMT of PCa cells in vitro via directly and negatively mediating KPNA2 expression.
conclusionsmiR-221-3p down-regulation was a risk factor for PCa BRFS, and its over-expression could inhibit the malignant phenotype and EMT of PCa cells by directly targeting KPNA2. Translational and personalized applications of the findings will be conducted in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.